Chelsea Therapeutics International (NASDAQ: CHTP)
Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses to acquire and develop products for the treatment of various human diseases. The company develops prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and cancer. It also develops therapeutic agent for the treatment of neurogenic orthostatic hypotension and related conditions, and diseases. In addition, the company develops platform technologies that consist of a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, and I-3D portfolio, a dihydroorotate dehydrogenase inhibiting compound. Chelsea Therapeutics' product in development includes CH-1504, an orally available molecule for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, psoriatic arthritis, and cancer. The company was incorporated in 2002 and is based in Charlotte, North Carolina.
Chelsea has a balanced portfolio of novel therapeutic agents that address disease states that correspond to significant unmet medical need. Investigational product candidates in the Chelsea pipeline include droxidopa, which is being evaluated for its potential use in indications which we believe norepinephrine may play a role, as well as a library of metabolically inert antifolate medications, including two clinical-stage products, CH-4051 and CH-1504, for the treatment of rheumatoid arthritis and other autoimmune diseases.
Behind these late and mid-stage products is a complementary portfolio of dihydroorotate dehydrogenase (DHODH) inhibitors, known as I-3D, which may have applications in treating autoimmune diseases and transplant rejection.
Monday, 09/28/2009 - Schedule 13G - http://www.irconnect.com/mc/irc/secfilings.mc?cmd=disp&id=6816624&type=HTML
Tuesday, 09/29/2009 - Schedule 13D - http://www.irconnect.com/mc/irc/secfilings.mc?cmd=disp&id=6818700&type=HTML